Lisdexamfetamine

Lisdexamfetamine is a prodrug — an inactive compound that the body converts into the active drug d-amphetamine (dextroamphetamine) ^{[1, 2]}. This prodrug design is the key feature that distinguishes lisdexamfetamine from other stimulant medications.

The molecule consists of the amino acid L-lysine chemically bonded to d-amphetamine. After oral ingestion, enzymes in red blood cells gradually cleave the lysine from the amphetamine, releasing active d-amphetamine into the bloodstream at a controlled rate ^{[1, 2, 3]}. This enzymatic conversion:

1. Provides smooth, extended-release delivery lasting up to 14 hours from a single dose — without the peaks and troughs of immediate-release stimulants or the variable absorption of bead-based extended-release formulations ^{[1, 2]}.

2. Reduces abuse potential: Because the active drug must be liberated by enzymes in the body, crushing, snorting, or injecting lisdexamfetamine does not produce the rapid "rush" associated with amphetamine abuse. Studies show that intranasal and intravenous lisdexamfetamine produces significantly lower "drug liking" scores compared to equivalent doses of d-amphetamine ^[3].

Once converted, d-amphetamine works by increasing dopamine and norepinephrine levels in the prefrontal cortex and other brain regions critical for attention, executive function, and impulse control ^{[1, 2]}. It does this by: - Blocking the reuptake of dopamine and norepinephrine - Promoting the release of these neurotransmitters from nerve terminals - Weakly inhibiting monoamine oxidase (MAO)

Your doctor will typically start at the lowest dose and gradually increase based on response and tolerability ^[1].

Week 1-2: You will likely start at 30 mg once daily in the morning. Effects begin within 1-2 hours and last up to 14 hours. You may notice improved focus, reduced impulsivity, and better task completion. Common early side effects include decreased appetite (especially at lunch), dry mouth, and difficulty falling asleep if taken too late in the day ^{[1, 2]}.

Week 2-4: Your doctor may increase the dose by 10-20 mg at weekly intervals. The target is the lowest effective dose that provides adequate symptom control throughout the day. Most patients stabilize at 50-70 mg/day for ADHD ^[1].

Ongoing: Unlike antidepressants, stimulants work from the first dose — there is no "build-up" period. However, finding the optimal dose may take several weeks of titration. Effects are present on days you take the medication and absent on days you do not.

Important practical tips: - Take in the morning (before 10 AM) to avoid insomnia - Can be taken with or without food (food does not affect absorption) - Capsules can be opened and contents dissolved in water, yogurt, or orange juice - Appetite suppression is strongest at midday; eat a good breakfast and plan for evening nutrition - Stay well hydrated throughout the day

Lisdexamfetamine can be taken with or without food — the prodrug conversion (not gastric absorption) is the rate-limiting step, so food has minimal effect on drug levels ^[1].

Acidic foods and drinks: High-dose vitamin C (ascorbic acid) and very acidic beverages may theoretically reduce amphetamine levels by acidifying urine and increasing excretion. However, the effect of normal dietary amounts (orange juice, fruit) is generally minimal. Some patients report reduced duration of effect with high vitamin C intake ^[1].

Alcohol: Alcohol should be avoided. Stimulants can mask the sedative effects of alcohol, leading to excessive drinking and increased risk of alcohol poisoning. Additionally, both substances stress the cardiovascular system ^[1].

Caffeine: Many ADHD patients consume caffeine. Combining caffeine with lisdexamfetamine can increase anxiety, jitteriness, insomnia, and cardiovascular effects (heart rate, blood pressure). If you use caffeine, moderate your intake and avoid it in the afternoon ^[1].

Grapefruit: No clinically significant interaction with grapefruit juice ^[1].

Lisdexamfetamine is taken once daily in the morning ^[1]:

ADHD — Adults [1]: - Starting dose: 30 mg once daily in the morning - Titration: Increase by 10-20 mg at weekly intervals - Usual range: 30-70 mg/day - Maximum: 70 mg/day

ADHD — Children (6-17 years) [1]: - Starting dose: 30 mg once daily in the morning - Titration: Increase by 10-20 mg at weekly intervals - Usual range: 30-70 mg/day - Maximum: 70 mg/day

Binge Eating Disorder — Adults [1]: - Starting dose: 30 mg once daily in the morning - Titration: Increase by 20 mg at weekly intervals - Target dose: 50-70 mg/day - Maximum: 70 mg/day - Note: NOT indicated for weight loss

Administration options [1]: - Swallow capsule whole - Open capsule and dissolve contents completely in water, yogurt, or orange juice - Chewable tablet formulation also available (Vyvanse chewable)

Special populations [1]: - Renal impairment (GFR 15-<30): Maximum 50 mg/day - Renal impairment (GFR <15 or ESRD): Maximum 30 mg/day - Hepatic impairment: No adjustment needed

Drug holidays: Some clinicians recommend weekend or summer breaks for children to mitigate growth suppression. Evidence for this practice is mixed ^[2].

As of early 2025, generic lisdexamfetamine became available after the expiration of key patents, significantly reducing costs ^[1].

Brand Vyvanse pricing: Approximately $350-$450/month without insurance.

Generic pricing: Approximately $30-$80/month (cash price with discount programs); insurance copays typically $10-$30.

Insurance: Most insurance plans cover lisdexamfetamine, though many require prior authorization or step therapy (trial of methylphenidate first). Tier 2-3 on most formularies.

Manufacturer savings: The Vyvanse manufacturer (Takeda) previously offered copay assistance programs; check current availability with the switch to generics.

Comparison: Generic lisdexamfetamine is now cost-competitive with generic mixed amphetamine salts (Adderall) and generic methylphenidate (Ritalin, Concerta generics).

Pregnancy — Risk Category C [1]:

There are no adequate, well-controlled studies of lisdexamfetamine in pregnant women. Animal studies at high doses showed potential for fetal harm. Amphetamines cross the placenta ^[1].

Known risks with amphetamine use in pregnancy: - Neonatal withdrawal symptoms have been reported (agitation, feeding difficulties) - Some epidemiological data suggest a small association with low birth weight, preterm delivery, and neonatal complications - No consistent association with major structural birth defects - Untreated ADHD may itself contribute to pregnancy complications (impulsive behavior, accidents, poor self-care)

The decision to continue or discontinue lisdexamfetamine during pregnancy should be made with a prescriber, weighing the risks of fetal amphetamine exposure against the risks of untreated maternal ADHD ^[1].

Breastfeeding: Amphetamines are excreted in breast milk. The relative infant dose is estimated at 5-6% of the maternal weight-adjusted dose ^[1]. Potential effects on the nursing infant include irritability, poor sleep, and reduced feeding. The decision to breastfeed while taking lisdexamfetamine should consider the benefit of breastfeeding and the mother's clinical need for the drug. Monitor the infant for agitation and poor weight gain ^[1].

Generic lisdexamfetamine became available in 2023-2024 following patent expiration of Vyvanse ^[1].

Brand Vyvanse: Capsules (10, 20, 30, 40, 50, 60, 70 mg) and chewable tablets (10, 20, 30, 40, 50, 60 mg) Generic lisdexamfetamine: Available in equivalent strengths from multiple manufacturers

All generic versions are FDA-rated as therapeutically equivalent (AB-rated) to Vyvanse. There should be no difference in clinical effectiveness or safety.

Because lisdexamfetamine is a prodrug converted by the body's enzymes (not a formulation-dependent extended-release), there is less concern about generic variability compared to some ER stimulant formulations.